18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.

Ferdinand SeithAndrea ForschnerHolger SchmidtChristina PfannenbergBrigitte GückelKonstantin NikolaouChristian la FougèreClaus GarbeNina Schwenzer

Published in: European journal of nuclear medicine and molecular imaging (2017)

Our study indicates that whole-body 18F-FDG-PET might be able to reliably identify complete responders to PD1-therapy as early as two weeks after therapy initiation in stage IV melanoma patients. This might help to shorten therapy regimes and avoid unnecessary side effects in the future.

Keyphrases

end stage renal disease
pet ct
ejection fraction
newly diagnosed
positron emission tomography
chronic kidney disease
pet imaging
stem cells
cell therapy
preterm birth